Tradestie Institutional Equity Comparison Engine
NBP vs ALLO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NBP Overall Edge
NBP Captures Institutional Edge (4โ0 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to NBP (NBP) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NBP trades at 2.7x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ALLO at N/M Forward P/E and -4172.6% operating margin (-100.0% YoY). In options structure, NBP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ALLO sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
NBP
NBP 2.7x vs ALLO N/M Fwd P/E
Growth & Margin Winner
NBP
Op Margin 0.0% vs -4172.6% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner
NBP
1Y -81.0% vs -33.7% ยท 52W Pos 0% vs 1%
Options & Structure Winner
NBP
UNCLASSIFIED (N/A IV) vs BREAKDOWN (100th %ile IV)
NBP
US Equity
NBP
Institutional Equity
$0.79
-6.66% 1D
Market Cap
$96.3M
1M Return
-37.04%
1Y Return
-80.98%
Forward P/E
2.7x
Unified AI Score
51.9 / 100
HOLD
Tech 60.0
Fund 50.0
Flow 50.0
Mom 55.0
ALLO
NASDAQ
Allogene Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.80
-5.09% 1D
Market Cap
$286.5M
1M Return
-39.24%
1Y Return
-33.67%
Forward P/E
N/M
Unified AI Score
42.6 / 100
HOLD
Tech 25.0
Fund 49.0
Flow 70.0
Mom 59.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NBP -80.98%
ALLO -33.67%
Spread: +47.31 pp (ALLO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
NBP TTM Op. Margin: 0.0%
ALLO TTM Op. Margin: -4172.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NBP vs ALLO. Trailing 12-month operating profitability (NBP 0.0% vs ALLO -4172.6%) and valuation multiples (NBP 2.7x vs ALLO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NBP | ALLO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $96.3M | $286.5M | Larger Scale | ALLO |
| Trailing P/E Ratio Valuation | 2.7x | N/M | Lower Multiple | NBP |
| Forward P/E Ratio Valuation | 2.7x | N/M | Lower Multiple | NBP |
| Revenue Growth (YoY) Growth | +0.0% | -100.0% | Higher Growth | NBP |
| Operating Margin (TTM) Profitability | 0.0% | -4172.6% | Higher Margin | NBP |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -59.1% | -49.3% | Higher ROE | ALLO |
| 52-Week Range Position Momentum | 0% ($1โ$5) | 1% ($1โ$4) | Stronger Trend | Tie |
| Beta / 30D Volatility Risk Regime | 1.66ฮฒ ยท 81% Vol | 1.87ฮฒ ยท 79% Vol | Lower Realized Risk | ALLO |
| Unified Institutional Score Composite Signal | 51.9 / 100 (HOLD) | 42.6 / 100 (HOLD) | Higher Composite | NBP |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NBP vs ALLO Buy Guide
NBP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ALLO
BREAKDOWN
151d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NBP nor ALLO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.